{"id":77128,"date":"2026-02-05T12:04:40","date_gmt":"2026-02-05T12:04:40","guid":{"rendered":"https:\/\/english.saigonbiz.com\/vn\/exicure-announces-publication-in-annals-of-hematology-highlighting-rapid-stem-cell-mobilization-with-burixafor-in-patients-with-multiple-myeloma-and-lymphoma-undergoing-transplant\/"},"modified":"2026-02-05T12:04:40","modified_gmt":"2026-02-05T12:04:40","slug":"exicure-announces-publication-in-annals-of-hematology-highlighting-rapid-stem-cell-mobilization-with-burixafor-in-patients-with-multiple-myeloma-and-lymphoma-undergoing-transplant","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/exicure-announces-publication-in-annals-of-hematology-highlighting-rapid-stem-cell-mobilization-with-burixafor-in-patients-with-multiple-myeloma-and-lymphoma-undergoing-transplant\/","title":{"rendered":"Exicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing Transplant"},"content":{"rendered":"<div>\n<p><em>Phase 2 data demonstrate differentiated CXCR4 inhibition kinetics enabling same-day cell collection, with rapid lymphocyte mobilization supporting potential therapeutic applications beyond transplant<\/em><\/p>\n<p>REDWOOD CITY, Calif., Feb.  05, 2026  (GLOBE NEWSWIRE) &#8212; Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced the publication of results from a prior Phase 2 clinical study evaluating burixafor (GPC-100\/TG-0054), a highly selective CXCR4 inhibitor, in the journal\u00a0<em>Annals of Hematology<\/em>.<\/p>\n<p>The manuscript, titled \u201c<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Set4SjJU6_HSyfCiIySbIHBoK7acgdyNbfNGzrmbVoSoBUI9NqWm9JUoT90MrPdIG6EEvo__QgwP7qsVYtRDecxduTAGo7l7TwENcdRAmcfbw5HE0uiUocr-dodOtJJM6t5g_OfBmtZks3Oq7SYvT5r_2jAnwC6vL6sxcAGKH_FDkCWlK50UOB1xNyZ7RAd50wx_WYrO6W6AoA60fhHWQ_uae5CSocx4yqehIImoHLncvVH3BS7BhlrWz_P7p3esAknZ5DNtA37FrGPQe15PW0NlPNMps_QNj64iKVU5eLz1pl-stvZmT6E-_azoEDan\" rel=\"nofollow\" target=\"_blank\" title=\"Burixafor, a CXCR4 Inhibitor with a Differentiated Kinetics Profile: Results of a Phase 2 Study for Rapid Cell Mobilization in Multiple Myeloma and Lymphoma Patients Undergoing Transplant\">Burixafor, a CXCR4 Inhibitor with a Differentiated Kinetics Profile: Results of a Phase 2 Study for Rapid Cell Mobilization in Multiple Myeloma and Lymphoma Patients Undergoing Transplant<\/a>,\u201d reports results from a 12-participant, multi-center, open-label Phase 2 study (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=1udd6Llgb7we12BpaVP2mqkqOSGBMoZwQIwpetBeyNen-94G3nzZXj7lRuL8n1t0kR79Q1qo3rRGLJGyV-scszeVUxLsac47jaMRu17-S1gwZrlqcvjAaJLdKxb47dv8\" rel=\"nofollow\" target=\"_blank\" title=\"NCT02104427\">NCT02104427<\/a>) evaluating burixafor in combination with granulocyte colony-stimulating factor (G-CSF) in patients with multiple myeloma (MM), non-Hodgkin\u2019s lymphoma (NHL), and Hodgkin disease (HD) undergoing autologous stem cell transplantation (ASCT).<\/p>\n<p>In the study, 11 of 12 participants (92%) met the primary endpoint of collecting \u22655.0 \u00d7 10\u2076 CD34+ cells\/kg within two leukapheresis sessions, with six participants achieving the target in a single session. Median time to neutrophil and platelet engraftment was 12 and 22 days, respectively. Burixafor was generally well tolerated, with only two treatment-related adverse events reported, both low grade.<\/p>\n<p>Notably, peak mobilization of CD34+ cells occurred within one hour of burixafor administration, substantially faster than currently approved CXCR4 inhibitors, which typically peak 10-14 hours after dosing. This rapid mobilization profile enables same-day leukapheresis, offering the potential to simplify treatment logistics, reduce hospital resource utilization, and minimize patient burden.<\/p>\n<p>In addition to robust stem cell mobilization, burixafor in combination with G-CSF led to marked increases in circulating white blood cell subsets, including lymphocytes. In participants with MM, lymphocyte counts increased by up to 11-fold within hours of burixafor administration, supporting potential applicability in gene therapy, CAR-T, and other gene-editing workflows that require efficient peripheral blood cell collection.<\/p>\n<p>\u201cASCT remains a treatment cornerstone for multiple myeloma and certain lymphomas. Efficient mobilization of peripheral blood progenitor cells is critical to achieving reliable engraftment while minimizing patient burden and overall healthcare costs,\u201d said Michael Schuster, MD, Clinical Professor of Medicine at Stony Brook University and a study author. \u201cIn this study, burixafor demonstrated enhanced mobilization kinetics that led to significantly faster attainment of stem cell collection goals, highlighting its differentiated profile and potential to meaningfully improve the efficiency of cell collection for ASCT. Beyond transplant, rapid and predictable mobilization of CD34-positive cells and lymphocytes may also be highly relevant for emerging gene-based and gene-editing approaches, including those being explored for conditions such as sickle cell disease.\u201d<\/p>\n<p>Exicure continues to advance burixafor\u2019s clinical development and has recently completed an additional Phase 2 study evaluating burixafor in combination with G-CSF and propranolol in patients with multiple myeloma undergoing autologous hematopoietic cell transplantation (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ieXdtgj3LoHCDIjsvhJvBuZGaqXZUokzwAcEuXQCACYdZmECiE3PMKQMSIQNidUXqWEO_cVfROOuLuCDTSNhc2FxM3cqX8P1QzdsQQ6Qy8WGvC4aTcbCUrEpAQcTp6cV\" rel=\"nofollow\" target=\"_blank\" title=\"NCT05561751\">NCT05561751<\/a>). The addition of propranolol was informed by <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=iq1G2d7PyzG-_yqX_ZDnoUR3XOxV1wNG_1TiOIMagLzvK3bNfiJ5KdwT6uZO9TNfvAJfu-pT7CLcIAVrelpR0EZOk80U99wgCRJn32ajQl5yCv1rExH_7mim2dKwW3VYU7hE-d0UGm-PaEQY21HRmA==\" rel=\"nofollow\" target=\"_blank\" title=\"previously published preclinical data\">previously published preclinical data<\/a> demonstrating functional crosstalk between CXCR4 and beta-adrenergic receptors, suggesting the potential for enhanced mobilization through dual pathway blockade. Positive topline data from this recent study were presented at the American Society of Hematology (ASH) Annual Meeting in December 2025 and the Tandem Meetings in February 2026, further supporting burixafor\u2019s differentiated and rapid mobilization profile in the transplant setting.<\/p>\n<p><strong>About Exicure<\/strong><br \/>Exicure, Inc. (Nasdaq: XCUR) is a clinical-stage biotechnology company developing therapies to address key challenges in hematologic diseases. The company\u2019s lead program, burixafor (GPC-100), is a highly selective small molecule antagonist of CXCR4, a chemokine receptor that plays a central role in retaining hematopoietic stem cells in the bone marrow niche. By blocking CXCR4, burixafor may enhance stem cell mobilization into the peripheral blood to support collection and use in autologous stem cell transplantation (ASCT).<\/p>\n<p>Burixafor is being evaluated for its potential to improve stem cell mobilization\u00a0in multiple myeloma, sickle cell disease, and in support of cell and gene therapy.\u00a0In addition, Exicure is planning a chemosensitization trial in acute myeloid leukemia (AML), leveraging burixafor\u2019s ability to mobilize malignant cells from protective bone marrow niches into the peripheral blood, where they may be more effectively targeted by chemotherapy. Burixafor became part of Exicure\u2019s pipeline following the company\u2019s acquisition of GPCR Therapeutics, Inc. in January 2025. For more information, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=baxmal01FypslKw9yEL8QkupaXFWlGE6VdtPDv-G7bgJooyrXnKcvL68tffSkGVD7I6EjonTKq1IYhupwnHXYnb68X_sbspeNB17WmOjMCM=\" rel=\"nofollow\" target=\"_blank\" title=\"www.exicuretx.com\">www.exicuretx.com<\/a>.<\/p>\n<p><strong>Media Contact:<\/strong><br \/><strong>Sarah Ellinwood, PhD<\/strong><br \/><strong>Kendall Investor Relations<\/strong><br \/><strong>sellinwood@kendallir.com<\/strong><\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NmM0MWUxNGQtN2JlMS00ODQzLTlmYjktMTMxYjhiMzQ0NjI2LTEwMzE4MDctMjAyNi0wMi0wNS1lbg==\/tiny\/Exicure-Inc-.png\" referrerpolicy=\"no-referrer-when-downgrade\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Phase 2 data demonstrate differentiated CXCR4 inhibition kinetics enabling same-day cell collection, with rapid lymphocyte mobilization supporting potential therapeutic applications beyond transplant REDWOOD CITY, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) &#8212; Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced the publication of results from a prior Phase 2 [&#8230;]\n","protected":false},"author":1,"featured_media":77129,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-77128","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pr-newswire"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v21.6 (Yoast SEO v21.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Exicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing Transplant - Biz and Live in Saigon<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/english.saigonbiz.com\/vn\/exicure-announces-publication-in-annals-of-hematology-highlighting-rapid-stem-cell-mobilization-with-burixafor-in-patients-with-multiple-myeloma-and-lymphoma-undergoing-transplant\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Exicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing Transplant\" \/>\n<meta property=\"og:description\" content=\"Phase 2 data demonstrate differentiated CXCR4 inhibition kinetics enabling same-day cell collection, with rapid lymphocyte mobilization supporting pot\" \/>\n<meta property=\"og:url\" content=\"https:\/\/english.saigonbiz.com\/vn\/exicure-announces-publication-in-annals-of-hematology-highlighting-rapid-stem-cell-mobilization-with-burixafor-in-patients-with-multiple-myeloma-and-lymphoma-undergoing-transplant\/\" \/>\n<meta property=\"og:site_name\" content=\"Biz and Live in Saigon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SaigonbizGroup\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-05T12:04:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/02\/Exicure-Inc-.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1\" \/>\n\t<meta property=\"og:image:height\" content=\"1\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/exicure-announces-publication-in-annals-of-hematology-highlighting-rapid-stem-cell-mobilization-with-burixafor-in-patients-with-multiple-myeloma-and-lymphoma-undergoing-transplant\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/exicure-announces-publication-in-annals-of-hematology-highlighting-rapid-stem-cell-mobilization-with-burixafor-in-patients-with-multiple-myeloma-and-lymphoma-undergoing-transplant\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\"},\"headline\":\"Exicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing Transplant\",\"datePublished\":\"2026-02-05T12:04:40+00:00\",\"dateModified\":\"2026-02-05T12:04:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/exicure-announces-publication-in-annals-of-hematology-highlighting-rapid-stem-cell-mobilization-with-burixafor-in-patients-with-multiple-myeloma-and-lymphoma-undergoing-transplant\/\"},\"wordCount\":719,\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"articleSection\":[\"Pr Newswire\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/exicure-announces-publication-in-annals-of-hematology-highlighting-rapid-stem-cell-mobilization-with-burixafor-in-patients-with-multiple-myeloma-and-lymphoma-undergoing-transplant\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/exicure-announces-publication-in-annals-of-hematology-highlighting-rapid-stem-cell-mobilization-with-burixafor-in-patients-with-multiple-myeloma-and-lymphoma-undergoing-transplant\/\",\"name\":\"Exicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing Transplant - Biz and Live in Saigon\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\"},\"datePublished\":\"2026-02-05T12:04:40+00:00\",\"dateModified\":\"2026-02-05T12:04:40+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/exicure-announces-publication-in-annals-of-hematology-highlighting-rapid-stem-cell-mobilization-with-burixafor-in-patients-with-multiple-myeloma-and-lymphoma-undergoing-transplant\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/exicure-announces-publication-in-annals-of-hematology-highlighting-rapid-stem-cell-mobilization-with-burixafor-in-patients-with-multiple-myeloma-and-lymphoma-undergoing-transplant\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/exicure-announces-publication-in-annals-of-hematology-highlighting-rapid-stem-cell-mobilization-with-burixafor-in-patients-with-multiple-myeloma-and-lymphoma-undergoing-transplant\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/english.saigonbiz.com\/vn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Exicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing Transplant\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"name\":\"Biz and Live in Saigon\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\",\"name\":\"SaigonBiz Media\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"width\":512,\"height\":512,\"caption\":\"SaigonBiz Media\"},\"image\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/SaigonbizGroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/english.saigonbiz.com\/vn\"],\"url\":\"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Exicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing Transplant - Biz and Live in Saigon","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/english.saigonbiz.com\/vn\/exicure-announces-publication-in-annals-of-hematology-highlighting-rapid-stem-cell-mobilization-with-burixafor-in-patients-with-multiple-myeloma-and-lymphoma-undergoing-transplant\/","og_locale":"en_US","og_type":"article","og_title":"Exicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing Transplant","og_description":"Phase 2 data demonstrate differentiated CXCR4 inhibition kinetics enabling same-day cell collection, with rapid lymphocyte mobilization supporting pot","og_url":"https:\/\/english.saigonbiz.com\/vn\/exicure-announces-publication-in-annals-of-hematology-highlighting-rapid-stem-cell-mobilization-with-burixafor-in-patients-with-multiple-myeloma-and-lymphoma-undergoing-transplant\/","og_site_name":"Biz and Live in Saigon","article_publisher":"https:\/\/www.facebook.com\/SaigonbizGroup","article_published_time":"2026-02-05T12:04:40+00:00","og_image":[{"width":1,"height":1,"url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/02\/Exicure-Inc-.png","type":"image\/png"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/english.saigonbiz.com\/vn\/exicure-announces-publication-in-annals-of-hematology-highlighting-rapid-stem-cell-mobilization-with-burixafor-in-patients-with-multiple-myeloma-and-lymphoma-undergoing-transplant\/#article","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/exicure-announces-publication-in-annals-of-hematology-highlighting-rapid-stem-cell-mobilization-with-burixafor-in-patients-with-multiple-myeloma-and-lymphoma-undergoing-transplant\/"},"author":{"name":"admin","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6"},"headline":"Exicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing Transplant","datePublished":"2026-02-05T12:04:40+00:00","dateModified":"2026-02-05T12:04:40+00:00","mainEntityOfPage":{"@id":"https:\/\/english.saigonbiz.com\/vn\/exicure-announces-publication-in-annals-of-hematology-highlighting-rapid-stem-cell-mobilization-with-burixafor-in-patients-with-multiple-myeloma-and-lymphoma-undergoing-transplant\/"},"wordCount":719,"publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"articleSection":["Pr Newswire"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/english.saigonbiz.com\/vn\/exicure-announces-publication-in-annals-of-hematology-highlighting-rapid-stem-cell-mobilization-with-burixafor-in-patients-with-multiple-myeloma-and-lymphoma-undergoing-transplant\/","url":"https:\/\/english.saigonbiz.com\/vn\/exicure-announces-publication-in-annals-of-hematology-highlighting-rapid-stem-cell-mobilization-with-burixafor-in-patients-with-multiple-myeloma-and-lymphoma-undergoing-transplant\/","name":"Exicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing Transplant - Biz and Live in Saigon","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#website"},"datePublished":"2026-02-05T12:04:40+00:00","dateModified":"2026-02-05T12:04:40+00:00","breadcrumb":{"@id":"https:\/\/english.saigonbiz.com\/vn\/exicure-announces-publication-in-annals-of-hematology-highlighting-rapid-stem-cell-mobilization-with-burixafor-in-patients-with-multiple-myeloma-and-lymphoma-undergoing-transplant\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/english.saigonbiz.com\/vn\/exicure-announces-publication-in-annals-of-hematology-highlighting-rapid-stem-cell-mobilization-with-burixafor-in-patients-with-multiple-myeloma-and-lymphoma-undergoing-transplant\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/english.saigonbiz.com\/vn\/exicure-announces-publication-in-annals-of-hematology-highlighting-rapid-stem-cell-mobilization-with-burixafor-in-patients-with-multiple-myeloma-and-lymphoma-undergoing-transplant\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/english.saigonbiz.com\/vn\/"},{"@type":"ListItem","position":2,"name":"Exicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing Transplant"}]},{"@type":"WebSite","@id":"https:\/\/english.saigonbiz.com\/vn\/#website","url":"https:\/\/english.saigonbiz.com\/vn\/","name":"Biz and Live in Saigon","description":"","publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/english.saigonbiz.com\/vn\/#organization","name":"SaigonBiz Media","url":"https:\/\/english.saigonbiz.com\/vn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","width":512,"height":512,"caption":"SaigonBiz Media"},"image":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SaigonbizGroup"]},{"@type":"Person","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","caption":"admin"},"sameAs":["https:\/\/english.saigonbiz.com\/vn"],"url":"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/77128","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/comments?post=77128"}],"version-history":[{"count":0,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/77128\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media\/77129"}],"wp:attachment":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media?parent=77128"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/categories?post=77128"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/tags?post=77128"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}